ReviewFrontiers in immunology2026
Multiple sclerosis as an asynchronous neuroinflammatory system.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) has traditionally been conceptualized through an event-based framework in which relapses, lesion accumulation, and disability progression evolve along a linear temporal axis. However, converging pathological, imaging, biomarker, and clinical trial evidence indicates that inflammatory activity, chronic lesion expansion, axonal degeneration, and network reorganization unfold with partially independent temporal dynamics. The 2024 revisions of the McDonald criteria formally incorporate markers of immune persistence and chronic inflammatory organization. Dissemination in space (DIS) remains the diagnostic entry point with a relaxation for the need of dissemination in time (DIT) yet prognosis cannot be reduced to event frequency alone. Disability accumulation reflects the interaction between Relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA), revealing a decomposable hazard structure that challenges relapse-centered modeling. Traditional endpoints such as annualized relapse rate (ARR) and confirmed disability progression (CDP) capture partial projections of a higher-dimensional disease process. MS should therefore be understood not as an event-driven disorder but as a dynamically evolving system. Biological onset occurs before clinical presentation, diagnosis occurs at a threshold; progression unfolds as a trajectory through a multidimensional state space (MSS). Recognizing this distinction has direct implications for prognostic inference, trial design, biomarker integration, and state-dependent therapeutic modeling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.